Skip to main content
. 2018 Mar 22;103(6):1029–1037. doi: 10.3324/haematol.2017.186528

Figure 3.

Figure 3.

MYD88L265P assay and IGH-based approaches are superimposable. Comparison of MYD88 and IGH-based minimal residual disease monitoring (expressed as copies of mutation in 1×105 cells) in 23 samples from 10 patients shows a good degree of correlation (r2=0.64).